Wednesday, November 19, 2014

Emerging Growth Stocks: PROP .17 Growing Revenue and Pipeline on their breakthough oil capture technology from problem wells.

 
 
Sent: Tuesday, November 18, 2014 11:29 PM
Subject: PROP Sales commencing on their breakthough technology that captures oil from problem wells
 
 
 
Updating on PROP, given the growing revenue and pipeline of their breakthough, Plasma Pulse enhanced oil recovery.
 

Propell Technologies Group, Inc.

 
undefined
 
0.17 Down 0.00(1.73%) Nov 18, 3:24PM EST
Propell Technologies Group, Inc. (PROP)
 
 
 
Examining more notable news in the last month involving a sucessful deal/expansion of their of their Plasma Pulse technology.
 
 
 
NBT Equities expanded on the California expansion:
 
 
Propell Technologies (PROP) Gains Critical Competitive Advantage in $Billion CA Oil Services Market

Propell Technologies Group (OTCQB: PROP), the exclusive U.S. licensee of a plasma pulse technology for enhanced ... per treatment. #3 The California opportunity for PROPis huge…literally over $billion in annual oil services. NBTER is preparing a new report onPROP that talks about their huge new opportunity in California. A new highly ...

News (NBT Contributors, start here!) - Tobin Smith - 10/20/2014 - 

Excerpt: 

Key Points:

#1 These wells were undoubtedly with major oil companies. Virtually all producing wells in the Bakersfield area are connected to Occidental/Chevron/Exxon/Marathon complex.

#2 These are full price deals—that is $20,000 to $25,000 per treatment.

#3 The California opportunity for PROP is huge…literally over $billion in annual oil services. NBTER is preparing a new report on PROP that talks about their huge new opportunity in California. 

Read more: 
 
 
 
Technical:  Holding support at .15 currently...Noticing a double bounce at it in the last wk.
 
 
 
 
Bottom Line:  While the technicals not so good, what is good is the initial success of their Plasma product launch...We suspect with the success at Miller Energy and California, more will follow...Look for bottoming out on this undeserving beaten down at .15 initially....Target a climb back above .20 initially.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Back in August we first brought to attention the launch of their new technology that recovers oil from problem wells...
 
Sent: Wednesday, August 20, 2014 2:12 AM
Subject: PROP Sales set to commence on their breakthough technology that captures oil from problem wells following deal with Miller Energy.
 
 
Examining PROP closer due to successful oil well treatment with Miller Energy. 
Set to go big with their breakthrough, oil capturing technology in light of success.
 

Propell Technologies Group, Inc. (PROP)

 -OTC BB
 
 
 
Earlier in August we issued a coverage report on PROP.  While remains rangebound in .20's, growing conviction .20 will hold adds to risk/reward-least downside risk factoring....
 
Keep in mind PROP's oil capturing technology has already landed several clients in E. Europe.
 
         

        Propell Technologies Updates Shareholders on Recent Developments

        Company announces successful treatment of first two wells with its new U.S. engineered Plasma Pulse Tool and commencement of commercial sales with strengthened balance sheet

        HOUSTON, Aug. 19, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Propell Technologies Group (PROP), the exclusive US licensee of a plasma pulse technology for enhanced oil recovery (EOR) today announced the successful treatment of two of Miller Energy Resources' (MILL) wells using their new U.S. engineered Plasma Pulse tool.

        The treatment took place in Morgan and Scott counties in Tennessee on the Hannah Heirs #4 and Henry Bowling #1 wells, both of which have open-hole completions. The treatments were made by the U.S. Propell team who observed substantial increases in fluid levels on both wells immediately after treatment.

        This recent news is in addition to the following milestones achieved during the second quarter of 2014:

        • Elimination of all short-term convertible debt primarily through early repayment and partially through conversion
        • Consummation of financing of the sale of fixed price common stock with warrants with proceeds to the Company of in excess of $1,000,000
        • Commencement of full commercial stage

        In the second quarter of 2014, the Company derived commercial revenue from its well stimulation business from several U.S. well treatments and has experienced an increase in requests for proposals for potential bookings for new treatments.

        With the receipt of a redesigned and optimized single-wire line tool and commencement of full commercial sales, the Company expects accelerated revenue growth due to its ability to treat additional types of wells with its streamlined and universally compatible treatment process.

        As highlighted above, the Company has strengthened its balance sheet though early repayment of most of its short-term debt preventing further share dilution and converted the remainder, eliminating all short-term convertible debt. In addition, the Company's cash runway is now stronger with the recent financing in which it raised in excess of $1,000,000.

        The Company believes it now has the financial flexibility to expand its commercial efforts and grow treatment sales.

        "With the receipt of our redesigned and optimized U.S. tool along with a stronger balance sheet we expect to now be able to strike contracts with significant operators like Miller Energy and enter into strategic sales relationships with influential channel partners," commented John Huemoeller II, President and CEO. "We expect this successful treatment of Miller Energy's wells to be the first of many using our new tool."

         

        Coverage we sent on PROP earlier in the month deserves a review, given the news:

         
        Sent: Thursday, August 7, 2014 12:15 PM
        Subject: PROP lands major deal on its breakthrough plasma related, micro fracking technology. Analyst calling it a game changer / predicts explosion in stock similiar to his call on Flotek in 2010,
         
         
        Focus stock:  PROP   Last .24
         
        Examining a recent, quite significant deal with PROP.
         
        First, the company pr:
         
        "We are looking forward to working with Miller Energy with the new U.S. made tools. We believe that this certainly opens up the market for us and we anticipate ordering several additional tools shortly thereafter," stated CEO John Huemoeller II.
         
         
        Aside from this new US deal, over 150 companies have utilized Novas Plasma Pulse Technology in the treatment and stimulation of oil wells throughout the Russian Federation, China, Kazakhstan, Uzbekistan and Czech Republic.
         
         
         
         
         
         
        In addition to the company PR, a separate report was issued by NBT Equities that contains some quite compelling information on the stock:
         
         
         
        In particular it cites Propell Technologies Group, Inc. (PROP) as game changer in the oil industry / huge ground floor opportunity. 
         
        Below is a portion of the report:
         

        This next-generation oil fracking technology has proven it can add $170 million to $340 million per DAY in new US oil production...and turn this tiny energy services company into the next $billion energy tech giant

        If you missed the $billions made from the first fracking technology stock boom stocks like:

          Check Mark5,557% gain in 35 months in Kodiak Energy (KOG)

          Check Mark1,372% gain in 22 months in Northern Oil and Gas (NOG)

          Check Mark3256% gain in Brigham Exploration in 28 months (BEXP)

        Don't miss the NEXT $Billions to be made in the American Oil Technology Revolution:

        Micro-Fracking from Propell Technologies (PROP)

        Dear Wealth Seeking Investor,

        Let's face it: achieving life-changing wealth in the 21st century is every investor's dream.

        For many investors, when they think about where the greatest wealth has been created recently in the United States, they think Silicon Valley...San Franciso.

        And they would be right. Recent studies of wealth creation in the first decades of the 21st century from the fine research folk at Wealth Insight shows that 2.07% of every resident of San Francisco is indeed a millionaire (>$1 million of assets outside of the value of their home).

        But what is MOST fascinating to me about this recent report—and MOST important to my special report today is "What major city in the United States OTHER than New York City—8 TIMES the population of San Francisco—has MORE millionaires per capita than San Francisco?

        Did you guess...

        ... "Houston Texas?"

        If you did, you're right. According to the Wealth Insight report 2.09% of Greater Houston's 6.4 million residents is a millionaire. And what new innovation/revolution created most of these new millionaires?

        The Shale Energy revolution of course...created by the revolutionary oil producing technologies of 1) horizontal drilling and 2)hydraulic fracturing or "fracking".

        Sorry Mark Zuckerberg or Elon Musk: it's a fact. FAR more billionaires and millionaires have been created in America from the Shale Energy Revolution and its amazing technology than all the Social Media/Cloud/Big data technology wealth combined.

        Now the question is...are you ready to make your fortune from the energy technology revolution in America?

        Great—let's get started on YOUR path to wealth.

        In the next few minutes I am going to make the case that THIS company is indeed one of the next millionaire makers in the energy technology miracle that I've come to call "Saudi America."

        Welcome to Saudi America...where the United States is fast replacing Saudi Arabia as the world's biggest oil producer.

        Opportunity IS all around you...and yes fortunes ARE being made daily in Saudi America.

        But our story today is about a revolutionary technology that brings the miracle of fracking technology to the billions of barrels of oil that already EXIST in America.

        I believe shareholders in this company stand to make the same kind of money early investors made in another little energy technology company I discovered in 2010.

        That company is Flotek Industries (FTK)—it's a fracking technology company—and its price chart tells a most compelling story of how a tiny Houston based company created thousands of millionaires from its energy fracking services technology.

        Flotek Industries(FTK)

        Fast forward to today.

        Propell Technologies...through its subsidiary Novas Energy...has exclusive rights to a similar game-changing technology to FloTek that has NOTHING to do with finding or extracting new oil deposits.

        The Novas Plasma-Pulse enhance oil recovery technology allows owners of the 420,000 EXISTING oil wells in the United States—specifically the ones producing less that 10 barrels a day—to double, triple and sometime gain up to 10 times the production from their existing wells.

        .....

        Summary: 10 Compelling Reasons Why PROP is a STRONG Buy TODAY under 50-60 Cents

        1. PROP's Plasma-Pulse patented technology has been 100% successful in 200+ marginal oil wells worldwide increasing production at LEAST 175% over pre-treatment existing production (source: PROP data)
        2. The total U.S. market for re-activation/enhanced production of low/no production oil wells is +550,000 stripper, injection and shut-in wells (source: United States Energy Information Agency (EIA)
        3. After drilling 2.6 million oil wells, over 50% of ALL the oil EVER discovered in the United States remains unrecovered and still in the ground (source: EIA)
        4. 45,000 NEW oil wells are projected to be drilled in the next 5 years in the United States (source: EIA)
        5. 150 oil companies—6 majors—have tested and proved PROP's Plasma-Pulse technology SAFE (source: Novas Energy website)
        6. PROP just introduced an American made 2.0 verion of its Plasma-Pulse tool which can treat 4.5" cases wells which represent the vast majority of US vertical wells. Since the original tool was too large to treat these 4.5" wells, significant new revenues are now available to PROP.
        7. Plasma-Pulse Micro-fracking is 100% Environmentally SAFE vs. Hydro-Fracking (source: Novas Energy website)
        8. Plasma-Pulse Micro-fracking is up to 95% LESS costly than hydro-fracking existing wells (source: NBT estimate)
        9. Near term elimination of ALL PROP convertible debt will reduce downward pressure on the stock
        10. Our price target for PROP is 8-10X HIGHER than today's price for PROP

        for more:   http://www.nbtequitiesresearch.com/company/propell-technologies-group-inc-prop/report/nbt-equities-research-initiating-coverage-on-propel-technologies-group-inc-prop

         

         

         

         

        In addition to 8/6 news, there are other signs this technology is about to get discovered as they have recently beefed up their staff, in addition to presenting at various....

        Milestone Expected to Result in Larger Addressable Market, Easier Operation and Greater Compatibility with US Wireline Configurations.

        .....the company expects to be able to treat the estimated 1 million US vertical and directional wells in its market as opposed to onlqy those with 5.5" casings, estimated to be about half of those in the US. 

        "With this next gen tool we should be in a position to treat most any vertical well in the country using any wireline truck. Until now we've had to turn away opportunities to treat otherwise ideal wells due to undersized well casings and wireline incompatibility," stated CEO John Huemoeller II. "This is a milestone that we expect to provide significantly greater revenue and profitability going forward."

         

         

         

         

        Bottom line:  PROP is beginning to bear fruit on a true game changing technology within the oil industry.  Combined with ongoing support near current levels, the risk reward ratio is quite appealing.  As a result, look for a pickup developin on this stock into 2014

         

         

         

         

        Disclosure:   Greenbackers does receive compensation from NfBT Equities from time to time to assist in expanding awareness for emerging growth companies they cover.  This includes assisting with expanding awareness on PROP.  NBT Equities is highly selective in companies they choose to sponsor.  They must meet their requirements including 'super secular growth' stocks.
         
         
         
        Greenbackers will use reasonable efforts to include accurate and up-to-date information on this website but makes no representations, warranties or assurances of any kind as to the accuracy, currency or completeness of information. Access to and use of the content is at your own risk, and neither Greenbackers. nor any party involved in creating, producing, or delivering this site shall be liable for any damage of any kind arising out of, or resulting from, your access to, use of or inability to access or use this website, any omissions or errors in its content, or from your reliance on any information provided at this website.

        © Copyright Greenbackers.com Inc 2014
        All Rights Reserved
        Greenbackers.com is a service mark of Greenbackers
         
         
         
         
        To unsubscribe, reply to email with 'unsubscribe' in subject line.

         

        Posted by at No comments:

        Sunday, November 16, 2014

        SRER interesting late day surge friday: .12 +0.03(37.77%)

         
        Focus:
         
         
         
        Last thurs/friday we participated in a awareness campaign with SRER w/NBT, mainly centering around 300% rev growth/providing afforbable housing in fast growing, oil boom towns, etc.  .....Emails, etc. from our blitz went out into the day on friday.......While volume was under avg, one or more of the contacts may have caught wiff.......
         
        .12 has been intermediate upside resistance....Expect it to break/head to .15-.20 into the month.....We are...

        SearchCore, Inc. (SRER)

         
        0.12 +0.03(37.77%) OTC Markets - As of 3:57PM EST
         
        SearchCore, Inc. (SRER)
         
         
         
         
         
         
         
         
         
        Posted by at No comments:

        Thursday, November 13, 2014

        Examining ZENO on Ebola related report....Interesting trending

        Focus:
         
        SRER flat at .10, however volume remains above avg.....Still for retesting .12 following oct run from .05 to .12
         
        52wk Range: 0.04 - 0.16
        Volume: 57,375
        Avg Vol (3m): 32,809
        Market Cap: 4.29M
         
         
        ACOL update....Looking like it wants to establish new lower support at .30...?
        Acology Inc  (ACOL)
        $ 0.31   0.0099 (+3.30%) Volume: 10.05
         
         
        undefined
         
        Passing along an interesting report recently released from NBT Equities......Has plenty of catalysts going for it including the role it could play with Ebola situation....Jumping back above .50 a real possibility....
         
        undefined

        Zenosense, Inc. (ZENO)

        -Other OTC
        0.43 Up 0.02(4.88%) 12:52PM EST
         
        Day's Range: 0.40 - 0.44
        52wk Range: 0.25 - 0.60
        Volume: 334,048
        Avg Vol (3m): 179,217
        Market Cap: 21.04M
        Quotes delayed, except where indicated otherwise. Currency in USD.
         
         
         
         
        By Tobin Smith | November 12, 2014, 11:59am GMTundefined

        Ticker: OTCQB: ZENO
        Website:         www.zenosense.net

         

        It's been all over the TV. Masked health workers screening airplane passengers for elevated body temperatures that can signal Ebola infection.

        They're screening with a simple "temperature gun." It's not fool-proof by a long shot. But it's all that's currently available. Even this elementary screening could potentially save millions of lives by early detection and preventing an Ebola-infected traveler triggering a world-wide pandemic.

        Hopefully, Ebola will be contained. And while each of its victims is a tragic loss, the highly-publicized Ebola outbreak has drawn the world's attention to the life-or-death importance of early and reliable detection of all deadly diseases.

        Ebola may be in the spotlight for now, but it pales in comparison to the persistent number of deaths caused every year by cancer, MRSA and other infectious diseases. And other epidemics and pandemics are bound to occur. Remember, the Spanish flu pandemic of 1918 is estimated to have killed as many as 100 million people. Early detection would have helped contain its spread.

        The Black Death of the Middle Ages, a bacterial infection carried by Oriental rat fleas living on black rats, is estimated to have taken the lives of 75 to 200 million people, 30% to 60% of Europe's population at the time. Of course there were no screening devices available back then. Had there been, millions of lives may have been saved by isolating the infected at an early stage.

        So, while the Ebola outbreak is indeed terrible, it may serve to focus the world's attention on 

        the critical need to develop more-effective, instant-response detection devices for all of the world's killer diseases.

        There's no doubt about it; the ready availability of an inexpensive, hand-held, instant-detection device for Ebola would have saved thousands of lives, and it would be in universal demand.

        In the not too distant future, there is real hope one will be available!

        Zenosense, Inc. is a high-tech medical device development company based in Valencia, Spain.

        Its mission is to develop market and sell low-cost, instant-answer detection devices, first for deadly MRSA and Lung Cancer, and perhaps, down the road, for other infectious and life threating diseases, including Ebola.

        There is currently no cost effective system that. . .

        a) acts like a "Smoke Alarm" for MRSA, detecting infection early, both in the patient or in the rooms of a healthcare building . . .

        b) acts as a simple, inexpensive and non-invasive test for the detection of Lung Cancer

        But, Zenosense is developing two novel detection devices that use high-tech chips to detect disease signature molecules in the exhaled breath of a suspect patient.

        One device is designed to detect the Methicillin-resistant Staphylococcus aureus "Super-Bug" (MRSA); and a second device screens for Lung Cancer.

        Both operate on a common "Electronic Nose" technology platform that analyzes Volatile Organic Compounds (VOCs) present in the exhaled breath of infected patients, scanning for certain biomarkers which can indicate the presence of deadly MRSA or lung cancer.

        The Company is capitalizing on an enormous latent dem

        and for a cost-effective MRSA and Lung Cancer detectors. Using licensed-in technology, it plans to produce devices for sale to healthcare providers for use in clinical settings. This unmet need is driven by the catastrophic costs and mortality rates associated with the late detection of both MRSA and Lung Cancer. It represents a new market segment potentially worth billions.

        More about how exactly these "Electronic Noses" work in a moment. Firstly, let's consider the need and market for these devices - and what it means in the way of profits for the technology company that is developing them.

        Think about it. . .

        Have you ever had the feeling that something was not quite right, but put off going to a doctor because you didn't want to undergo a time consuming, expensive battery of blood tests, scans or x-rays?

        Well. . .what if getting initially screened for an infectious disease or even lung cancer were as simple, quick and easy as blowing into a tube? And what if you'd discover in a matter of seconds if you were likely okay or requiring the immediate treatment that may save your life? Managed care being what it is today, you had better believe that every doctor, clinic and hospital would be required to have these early detection devices readily and abundantly on hand.

        Inc. (ZENO) is already well into the development of early-detection dev

        ices for MRSA and Lung Cancer, two of the most common causes of death in America.

        MRSA is a killer bacterium responsible for difficult-to-treat deadly infections.

        MRSA is any strain of Staphylococcus aureus ("SA") that has developed a resistance to antibiotics, including the penicillins such as Methicillin, Dicloxacillin, Nafcillin, Oxacillin, and also the Cephalosporins group.

        MRSA has recently been estimated to be responsible for 11,000 deaths and 80,000 invasive infections per year in the United States alone.

        Patients with MRSA can be twice as likely to die as patients with non-resistant Staph infections that can be treated. The annual costs of treating hospitalized MRSA patients are between $3.2 billion and $4.2 billion in the United States alone (according to an Issue Brief released by the Pew Charitable Trust on April 3, 2012).

        The high financial toll on private and public health care systems by MRSA is clearly a critical issue for healthcare providers and authorities.

        A considerable and expensive effort is directed at early identification of infected patients, However lab tests from cultured samples typically involve extensive incubation times of 24 hours or more and a 2-3 day result turnaround. Other tests are also available with shorter (just hours) turnaround times but these are more expensive.

        Deadly infections like MRSA, acquired in healthcare settings (known as HAI's) affect hundreds of millions of patients worldwide, leading to significant mortality and financial losses for health systems. In developed countries 7 of every 100 hospitalized patients will acquire at least one HAI. In developing countries it's 10 in every 100.

        The Centers for Disease Control and Prevention (CDC), part of the US Department of Health and Human Sciences, estimate that one in 20 patients treated in U.S. hospitals develop an HAI. Approximately 2 million HAIs are associated with nearly 100,000 deaths each year and are directly responsible for at least 23,000 deaths per year in the United States alone.

        The CDC takes the view that advanced molecular detection technologies, which can iden

        tify threats much faster than current practice, are not being used as widely as necessary in the United States: Developing better diagnostic tools to rapidly and accurately find sources of contamination will improve antibiotic use. Zenosense's MRSA detection device is designed to meet that explicit need.

        Recent studies suggest that early detection could result in a 70 per cent reduction in certain HAIs .

        A recent report released by CDC estimates early-detection could save $25.0 billion to $31.5 billion in medical cost just in the United States alone. MRSA continues to account for a significant proportion of HAIs and is regarded as one of the most important causes of antimicrobial-resistant HAIs worldwide.

        What's urgently needed is a life-saving, low-cost early-detection device for MRSA. Zenosense is in the business of providing it.

        Lung cancer - another common killer

        In the U.S. alone there are an estimated 226,150 new cases of lung cancer every year, resulting in some 164,770 deaths. The primary reason lung cancer is so deadly is that only 30% of diagnoses are made in the early stages of the disease. Stage 1 has a 70% cure rate, while patients with a late stage diagnosis have a much reduced, 25% chance of survival.

        Consequently there is an urgent need to detect lung cancer at an early stage. In 2002 the National Lung Screening Trial (NLST) was launched, using Computed Tomography (CT) for rapid screening at low dose. It proved to be costly, but effective, albeit carrying concerns about the side effects of the scans.

        Zenosense is developing a safe, non-invasive diagnostic breath test for the detection of lung cancer with effectiveness at least comparable to CT screening - but without the health risks and high costs.

        The Company believes there will be an enormous demand for such a mass screening device to

        be used in conjunction with other testing, if required. And the Company's ultimate aim is to deliver a device which can perform a definitive test at very high levels of accuracy which again is safe, fast, non-invasive and available at a substantially lower cost compared to existing testing methods.

        These Electronic Sniffers Could Save Your Life.

        Electronically "Sniffing" to detect disease is based on proven natural processes. You see it in highly trained dogs that are able to detect prostate cancer with 98% accuracy, simply by sniffing urine samples.

        While humans have roughly five million olfactory cells in their noses, dogs have about 200 million. This natural, learned detection by multiple sensors is analogous to the Zenosense technology platform. This, by clever electronic processing, effectively utilizes an infinite number of sensors and software that "learns" to recognize the relevant VOCs (Volatile Organic Compounds) related to specific diseases.

        Development work is being carried out by a team of experts in nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry. Collaborations and partnerships are also in place with hospitals, universities and a private laboratory in the fields of sensors, polymer electrochemistry, microbiology, infectious disease, pneumology, chromatography and microorganism identification.

        The cost of these life-saving devices will be kept low through the utilization of standard components, but will be centered on the patent-pending Sgenia chip (under license to Zenosense). Its pre-programed software enables a standard sensor to scan for a disease's signature compounds.

        A patient's breath is electronically processed by patent-pending Sgenia hardware. The algorithmic software is protected as an Industrial Secret by FPGA (Field Programmable Gate Array) "lock and key" encryption on Sgenia's chip.

        A single Sgenia chip Is able to duplicate a screening process that previously required 8 to 32 sensors with supporting processors, circuit boards and power supply, each sensor pre-set to

        a detect a certain part of the VOC spectrum associated with a specific disease.

        This enables a huge cost saving over an array of individual sensors and allows the potential for mass scale production at an anticipated cost per device at an attractive price level that will encourage widespread adoption.

        The MRSA Detection Device

        Development of the MRSA detection device has been underway since December 2013. It is designed as single low cost sensors that sample the air and continuously monitor for the airborne VOC signature emitted by MRSA and treatable Staph (SA). The MRSA/SA VOC signature is only emitted when the bacteria has infected and expressed itself as a disease in the patient. It can be detected prior to the patient being obviously symptomatic, enabling an earlier intervention.

        The device is intended to be produced in two forms:

        1) A low cost wearable / bed positioned device, powered by a rechargeable battery to be positioned on the person; patients and medical staff. In the event of any infection, the MRSA device will detect the VOCs produced by the infected person and express an audio/visual alarm; and

        2) an adapted, fixed device positioned in the room, mains powered, with culture-amplification of any MRSA/SA presence, to monitor the room volume. This would be network monitored.

        The Sgenia detection technology is very sensitive. If the VOC signature of the genetically different MRSA can be separated from the signature of SA, there is a prospect that such a discriminatory device can be developed.

        The Lung Cancer Detection Device


        Development is well underway of a device into which a patient can blow during a routine health check or when displaying symptoms indicative of lung cancer.

        Similar to the MRSA device, it uses a single low-cost sensor to detect specific VOCs emitted only in the breath of a person affected with lung cancer. Related technology and detection principles used in the MRSA device (under development since December 2013) will be applied. The initial aim is to develop a device which can be used as a complimentary test to existing tests such as Tomography scans, and to match or exceed the accuracy of these scans.

        The aim is for the device to be low cost and non-invasive and therefore affordable in the basic primary care setting such as a family physician.

        Such a device would be in universal demand and provide the solution for mass screening for lung cancer in a safe and cost effective manner, overcoming some of the shortfalls of other forms of mass screening. The ultimate goal is to develop a device which can provide a very high level of accuracy and act as a definitive, non-invasive and low cost test.

        As the co-developer of these two novel, cost-effective detection devices, Zenosense is likely to be highly attractive to prospective distribution partners and end users. Each type of device has the potential to service a multi $billion market to address the critical and often lethal issues posed by these two conditions.

        Read more:
         
         
         
         
         
        NEO'S GOT NOTHING ON THESE TWO
        Spears Fly In This Mind-Bendingly Fast Martial Arts Demonstration
        digg.com
        These two martial artists are competing in an exhibition known as duilian, which pits a bare-handed combatant against a weapon-wielding opponent. We wouldn't want to face either of them, with or without a weapon.
        Posted by at No comments:
        Subscribe to: Posts (Atom)